BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy

Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD).

KiadisMAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, the company is developing T cell therapies to make bone marrow transplantations safer and more effective.

The Biotech’s lead candidate, ATIR101 is a T-cell immunotherapy that eliminates alloreactive cells from the donor to minimize the risk of GVHD after hematopoietic stem cell transplantation (HSCT), currently the most effective treatment for most blood cancers. The therapy has completed a pivotal Phase II study and is currently being investigated in Phase III for blood cancers in adults. With its innovative therapy, Kiadis is pioneering the field by going for a major issue in HSCT.


Images via shutterstock.com / angellodeco

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.